Search Results

You are looking at 1 - 10 of 271 items for :

  • "epidermal growth factor receptor" x
  • All content x
Clear All
Full access

Noman Ashraf, Nishi Kothari, and Richard Kim

agents and targeted therapies against both vascular endothelial growth factor and epidermal growth factor receptor (EGFR), survival has improved. However, outcomes remain highly variable because CRC is a heterogeneous multipathway disease. 2 , 3 It is

Full access

Helena A. Yu and Gregory J. Riely

Epidermal Growth Factor Receptors The epidermal growth factor receptor (EGFR) family includes 4 receptor tyrosine kinases: EGFR (HER1), ERBB2 (HER2), ERBB3 (HER3), and ERBB4 (HER4). The EGFR is composed of an extracellular ligand binding

Full access

Leora Horn

information, revealing whether the tumor is negative for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations, for instance. Histology guides treatment choices, and clinical trial data tend to support this approach. For

Full access

Barbara Burtness, Milan Anadkat, Surendra Basti, Miranda Hughes, Mario E. Lacouture, Joan S. McClure, Patricia L. Myskowski, Jennifer Paul, Clifford S. Perlis, Leonard Saltz, and Sharon Spencer

References 1 Mendelsohn J . Targeting the epidermal growth factor receptor for cancer therapy . J Clin Oncol 2002 ; 20 : 1s – 13s . 2 Castillo L Etienne-Grimaldi MC Fischel JL . Pharmacological background of EGFR

Full access

Jeremy D. Kratz, Nataliya V. Uboha, Sam J. Lubner, Daniel L. Mulkerin, Linda Clipson, Yanyao Yi, Menggang Yu, Kristina A. Matkowskyj, Noelle K. LoConte, and Dustin A. Deming

chemotherapy and targeted agents depending on distinct molecular profiles. Antibodies targeting epidermal growth factor receptor (EGFR), including cetuximab and panitumumab, have shown clinical utility in the late-line setting. 3 , 4 Defining populations most

Full access

Wells A. Messersmith

-approved drugs for use in colorectal cancer. Abbreviations: EGFR, epidermal growth factor receptor; TAS-102, trifluridine-tipiracil; VEGF, vascular endothelial growth factor. a VEGFR, BRAF, and others. The issue of cost remains a major concern in the treatment of

Full access

Gauri R. Varadhachary

: EGFR, epidermal growth factor receptor; IHC, immunohistochemistry. Several groups have studied the role of immunohistochemistry patterns and decision trees based on immunohistochemistry specificity, sensitivity, and predictive values. These data

Full access

Paul F. Engstrom

; EGFR, epidermal growth factor receptor; FOLFIRI, 5-FU, leucovorin, irinotecan; FOLFOX, 5-FU, leucovorin, oxaliplatin; IFL, irinotecan, 5-FU, leucovorin; VEGF, vascular endothelial growth factor. The 2007 version of the NCCN Guidelines for Colon

Full access

Robin K. Kelley, Grace Wang, and Alan P. Venook

that an activating mutation in the KRAS oncogene is a biomarker for tumor resistance to monoclonal antibodies targeting the epidermal growth factor receptor (EGFR); this has led to the widespread adoption of tumor KRAS mutational analysis before

Full access

Dung T. Le and Elizabeth M. Jaffee

; DC, dendritic cell; EGFR, epidermal growth factor receptor; GM-CSF, granulocyte-macrophage colony-stimulation factor; HER2, human epidermal growth factor receptor-2; IL, interleukin; PD-1, programmed death-1; VEGF, vascular endothelial growth factor